CHIT1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human spleen tissue and Human lung tissue lysates, Primary antibody: P09500(CHIT1 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P09500(CHIT1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P09500(CHIT1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CHIT1 antibody targets chitotriosidase-1 (CHIT1), a 50 kDa glycosidase belonging to the human chitinase family. CHIT1 is primarily secreted by activated macrophages and plays a role in hydrolyzing chitin, a structural polysaccharide in fungi, parasites, and insects. Though humans lack endogenous chitin, CHIT1 is implicated in innate immune responses, potentially aiding in pathogen clearance and tissue remodeling. Elevated CHIT1 activity is associated with several pathologies, including Gaucher disease (a lysosomal storage disorder), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and atherosclerosis, making it a biomarker for disease progression and macrophage activation.

CHIT1 antibodies are essential tools for research, enabling detection and quantification of CHIT1 in biological samples via techniques like ELISA, Western blot, and immunohistochemistry. These antibodies help elucidate CHIT1’s role in inflammatory and fibrotic pathways, particularly its contribution to macrophage-mediated tissue damage or repair. Recent studies also explore CHIT1’s dual role in metabolic syndromes and cancer, where its expression may influence disease mechanisms. Therapeutic interest in CHIT1 inhibition has grown, with antibodies aiding in validating drug candidates targeting chitinase activity. However, interpreting CHIT1 data requires caution due to genetic polymorphisms (e.g., the common 24-bp duplication mutation reducing enzyme activity) and cross-reactivity risks with homologous chitinases like AMCase. Overall, CHIT1 antibodies remain pivotal in advancing understanding of its biological and clinical significance.